Quick Answer
CytomX Therapeutics, Inc. reported Operating Income of -$22.36 million for fiscal year 2025.
CytomX Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$22.36M | -189.5% |
| 2024 | $25.00M | +485.5% |
| 2023 | -$6.48M | +93.6% |
| 2022 | -$101.33M | +12.7% |
| 2021 | -$116.04M | -138.7% |
| 2020 | -$48.60M | +56.2% |
| 2019 | -$110.89M | -42.4% |
| 2018 | -$77.87M | -68.3% |
| 2017 | -$46.26M | +22.4% |
| 2016 | -$59.59M | -79.5% |
| 2015 | -$33.20M | -11.6% |
| 2014 | -$29.77M | -99.0% |
| 2013 | -$14.96M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.77M | -483.6% | -1126.1% |
| June 30, 2025 | -$1.29M | +84.8% | -105.7% |
| March 31, 2025 | $22.62M | +94.1% | +450.3% |
| September 30, 2024 | $4.11M | +31.6% | +148.6% |
| June 30, 2024 | -$8.45M | -152.4% | -172.5% |
| March 31, 2024 | $11.66M | +306.2% | +273.3% |
| September 30, 2023 | $3.12M | +110.5% | +193.3% |
| June 30, 2023 | -$3.35M | +88.9% | +40.8% |
- CytomX Therapeutics, Inc. showed a decrease of -189.5% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, CytomX Therapeutics, Inc.’s operating income has declined by 49.5% (from -$14.96 million to -$22.36 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: